Exploring the frontier of cardiovascular pharmacotherapy

William L Baker¹, Cynthia A Jackevicius^{2

3

4

5}

Affiliations

¹ University of Connecticut School of Pharmacy, Storrs, Connecticut, USA.
² College of Pharmacy, Western University of Health Sciences, Pomona, California, USA.
³ VA Greater Los Angeles Healthcare System, Los Angeles, California, USA.
⁴ Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada.
⁵ ICES, Toronto, Ontario, Canada.

Editorial

William L Baker et al. Pharmacotherapy. 2021 Dec.

. 2021 Dec;41(12):968-969.

doi: 10.1002/phar.2645.

William L Baker¹, Cynthia A Jackevicius^{2

3

4

5}

¹ University of Connecticut School of Pharmacy, Storrs, Connecticut, USA.
² College of Pharmacy, Western University of Health Sciences, Pomona, California, USA.
³ VA Greater Los Angeles Healthcare System, Los Angeles, California, USA.
⁴ Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada.
⁵ ICES, Toronto, Ontario, Canada.

No abstract available

References

1. Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. Circulation. 2021;143:e254-e743. doi:10.1161/CIR.0000000000000950
1. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140:e596-e646. doi:10.1161/CIR.0000000000000678
1. Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2014;130:1749-1767.
1. Talasaz AH, Ho A, Bhatty F, et al. Meta-analysis of clinical outcomes of PCSK9 Modulators in patients with established ASCVD. Pharmacotherapy. 2021;12:1009-1023.
1. Barry A, Dixon D. Omega-3 fatty acids for the prevention of atherosclerotic cardiovascular disease. Pharmacotherapy. 2021;12:1056-1065.